# Lucence

Source: https://onco.cc/companies/lucence/  
OnCo record `lucence` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Lucence offers blood tests that read both tumour DNA and tumour RNA from a single sample to help doctors choose targeted treatments, and is developing a multi-cancer screening test.

## Summary

Lucence is a precision diagnostics company with laboratories in Singapore and Palo Alto, California, and an office in Hong Kong. Its AmpliMARK amplicon-based technology enables ultrasensitive detection of cell-free DNA and RNA. The flagship LiquidHALLMARK assay profiles circulating tumour DNA and RNA in one blood draw to identify actionable mutations and fusions in solid tumours, with a cerebrospinal fluid version for central nervous system cancers. LucenceINSIGHT is a multi-cancer early detection (MCED) test the company states screens at 99 percent specificity, and LucenceMONITOR addresses treatment monitoring. Laboratories are CAP-accredited and CLIA-certified. Data on combined ctDNA and ctRNA yield were presented at ASCO 2025, and in March 2026 Lucence, DxD Hub and the National Cancer Centre Singapore launched an S$6 million research collaboration.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Singapore
- Type: diagnostics
- Website: https://www.lucence.com/

## Notes

- No funding round could be sourced from primary releases on the company site; stage set to startup provisionally. Founding year not sourced. Cancer and target tags reflect typical LiquidHALLMARK coverage described generically on the site rather than a fetched panel list.

## Sources

- Official website: https://www.lucence.com/
- News and updates: https://www.lucence.com/news-updates
- About Lucence: https://www.lucence.com/about

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/), [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Comprehensive genomic profiling](https://onco.cc/technologies/cgp/), [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/), [RNA sequencing & expression profiling](https://onco.cc/technologies/rna-seq/)
- targets: [ALK](https://onco.cc/targets/alk/), [EGFR](https://onco.cc/targets/egfr/), [KRAS](https://onco.cc/targets/kras/), [MET](https://onco.cc/targets/met/), [NTRK](https://onco.cc/targets/ntrk/), [RET](https://onco.cc/targets/ret/)

---
JSON: https://onco.cc/api/v1/entities/lucence.json